Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Angers mounts in US over vast network of car license plate cams
-
Olympic weightlifter hoists debris for Venezuela earthquake recovery
-
Darderi to face Nakashima in Montreal quarter-finals
-
FIFA condemns 'concerted and ongoing effort' to weaken Infantino
-
Espresso power fires Darderi past Borges in Montreal
-
South Africa win after surviving late Argentina surge
-
Shnaider upsets Pegula to book Toronto quarter-final with Swiatek
-
Man Utd boss Carrick being 'careful' with Mount as Man Utd draw with PSG
-
Mount injury overshadows Man Utd draw with Paris Saint-Germain
-
All Black Tuipulotu surprised after Sharks include Nonu
-
Ukraine denies targeting Bulgaria as drone explodes near pipeline
-
Infantino denies allegations of affair, favouritism while at UEFA: report
-
Vollering grabs Tour de France lead in Nice
-
MotoGP leader Martin soars to victory in British GP sprint race
-
Euros to showcase new TV guidelines on non-sexualisation of women athletes
-
Mosimane set to succeed Broos as South Africa coach
-
'Calm' Kiss savours first win as Wallabies boss
-
Drone enters Bulgaria, explodes near pipeline at Romanian border
-
Duplantis bids for fourth European title as stars align in Birmingham
-
Paris orders e-scooter users to wear helmets, reflective gear
-
Ukraine warns of tough winter as Russia strikes kill 4 in Kyiv region
-
Lionel Messi's father Jorge dies aged 68
-
Recovering Marchand to skip medleys at European swim champs
-
Johnson reveals 'stress' of Grand Slam Track collapse, clarifies payment
-
MotoGP leader Martin speeds to British Grand Prix pole
-
Defending champion Ferrand-Prevot out of Tour de France Femmes
-
Drone enters Bulgaria, explodes near pipeline at Romanian border: Bulgarian PM
-
Wallabies squeeze past Japan to give Kiss a winning start
-
Arsenal sign Brazil midfielder Guimaraes from Newcastle
-
Kyiv mourns recovery volunteer, whose life 'intertwined with the fallen'
-
Atletico will not sell Alvarez, says Simeone
-
Only two vehicles earn perfect child-seat scores for 2026
-
Ford Fathom turns affordable electric pickup into reality
-
Chinese car brands reshape Australia’s automotive market
-
Lise Klaveness, the Norwegian thorn in Infantino's side
-
Electric cars enter their most decisive generation yet
-
Europe’s electric car boom exposes a widening market divide
-
Three Chinese carmakers enter the global automotive top 10
-
US Senate confirms Trump's ex lawyer as attorney general
-
Ukraine's Zelensky visits Russian ally Serbia as Moscow pounds Kyiv
-
Tibet conference in Nepal pushed online
-
Ukraine's Zelensky visits Russian ally Serbia for talks
-
Nocturnal 'coffee frog' discovered in Costa Rica
-
Defending champion Shelton storms to Montreal win
-
India's 'cockroach' protest movement keeps heat on Modi
-
Exodus: West Bank hardships drive out Palestinian Christians
-
Russia's only anti-war party eyes support boost at elections
-
Travis Head wins Australian cricketer of the year gong
-
Canada tries to adapt to a future of wildfires
-
Colombia's new president vows to 'defeat narco-terrorists'
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
A.P.Maia--PC
